Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025
Angela Rose, Héloïse Lucaccioni, Kimberly Marsh, Freja Kirsebom, Heather Whitaker, Hanne‐Dorthe Emborg, Amanda Bolt Botnen, Mark G. O’Doherty, Francisco Pozo, Safraj Shahul Hameed, Nick Andrews, Mark Hamilton, Ramona Trebbien, Karina Lauenborg Møller, Diogo Marques, Siobhán Murphy, Ross McQueenie, Jamie Lopez Bernal, Simon Cottrell, Magda Bucholc, Esther Kissling, European IVE group
Abstract
The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32-53% in primary care and 33-56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.